The ‘don’t eat me’ antidote: GlaxoSmithKline, Roche and Novo back $86M startup in high-stakes CD47 showdown
CD47 is a hot prospect in the immuno-oncology world. And Washington University spinout Tioma Therapeutics plans to be a player in that booming R&D game.
It’s an older startup, seeded for years to cover preclinical work but now prepping for a turn in the clinical spotlight. Today the company landed an $86 million launch round and an experienced biotech hand who is now at the helm. RiverVest Venture Partners co-led the round along with a trio of pharma heavyweights: Novo Ventures, Roche Venture Fund and GlaxoSmithKline’s S.R. One.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.